Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of Body Composition on Doxorubicin PK in Pediatric Patients
NCT00124956Phase 2Withdrawn
- Sponsor
- Boston Children's Hospital
- Start
- Jun 2003
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doxorubicin in cancer, sponsored by Boston Children's Hospital. Primary endpoint: Relationship between obesity and doxorubicin pharmacokinetics in children. Planned start Jun 2003; status: withdrawn.
02
Drugs
doxorubicin
03
Conditions
cancer
Beyond the preview
Go deeper on NCT00124956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00124956.